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Background Results (cont.)
Discussion and Conclusions
This study is exempt by Institutional Review Board
 Study design
Single-centered, quasi-experimental implementation study 
with retrospective review from February 25th, 2020 to April 
17th, 2020.
 Patient management program
• New patient assessment:
➢ Evaluate therapy appropriateness, monitoring 
parameters, patient history & baseline quality-of-life
➢ Perform medication reconciliation and drug interaction 
evaluation
➢ Manage REMS criteria and compliance
➢ Provide medication and non-pharmacological education. 
• Patient follow-up assessment:
➢ Evaluate medication efficacy, safety profile, monitoring 
parameters, medication adherence & disease impact on 
quality-of-life
➢ Perform medication reconciliation and drug interaction 
evaluation
➢ Manage REMS criteria and compliance
➢ Identify side effects and provide side effect management 
strategies, as appropriate.
 Study objectives and data analysis
• Primary objectives
Pharmacist competency and readiness based on targeted 
PAH/REMS education program and trainings. 
➢ Two on-site continuing education sessions
o First session: PAH Disease State/Therapeutics
o Second session: Targeted medication and REMS 
management
➢ Two pre-and post clinical assessments before workflow 
launch.
➢ Final clinical assessment one-month after workflow 
launch.
• Secondary objectives 
Pharmacist clinical interventions and satisfaction with 
PAH/REMS-focused education and resources.
➢ Post-implementation retrospective report based on 
specialty pharmacy electronic health record (EHR)
➢ Post- implementation pharmacist satisfaction survey
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Pulmonary Arterial Hypertension (PAH) is a progressive, and 
debilitating disease, often resulting in poor prognosis when 
treatment is inadequate:
❖ 1 to 3 years mortality rates as high as 30% 1,2,3
❖Medical costs are approximately four times higher due to 
drug cost and extensive medical oversight.
Health system specialty pharmacies have evolved over the past 
decade to adapt to an exponential growth of high-cost specialty 
drugs being approved for complex disease state.
Clinical pharmacists in specialty pharmacies are well-equipped 
to provide meaningful interventions in collaboration with PAH 
clinicians to improve patient care outcomes and reduce overall 
healthcare cost:
❖ Individualized assessment of disease state.
❖Medication reconciliation with drug interaction 
evaluation Assessment of monitoring parameters.
❖ Risk Evaluation & Mitigation Strategies (REMS) 
compliance.
❖ Evaluation of disease impact on patient quality of life.
❖ Side effect identification and management strategies.
❖ Safe and cost-effective medication fulfillment.
This study aims to develop and implement a PAH-specific 
clinical workflow, while providing enhanced pharmacist 
education, training & resources in a health-system specialty 
pharmacy setting.
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PAH/REMS Education and Workflow Implementation
1. The PAH education and training sessions met my expectations 
and was relevant to my clinical practice.
2. The PAH/REMS education and training sessions provided me 
with the resources I need to effectively assess patients and 
identify interventions that are safe and evidence-based.
3. After targeted REMS training, I feel more equipped to assess 
patient for REMS criteria prior to dispensing high risk PAH 
medications.
4. The new PAH-specific “new patient” and “patient follow-up” 
assessments provide appropriate platforms for my patient 
education and assessment needs.
5. The implementation phase of the PAH workflow allows for 
accurate and safe process to dispense PAH orders. 
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Primary and secondary results show upward trend in pharmacist 
competency and readiness following a series of targeted 
PAH/REMS education sessions and training. 
• Both pre/post assessments demonstrated a 70% increase in 
pharmacist competency.
• High level of proficiency was sustained one month after the 
rollout of the new workflow with mean competency 
remaining at 85% or above.
• The 67% increase in overall pharmacist readiness further 
demonstrated pharmacist competency in PAH management. 
A retrospective EHR review from February 25th, 2020 to April 
17th, 2020 demonstrated that clinical pharmacists are equipped 
to provide thorough patient education, disease assessment, 
medication management, REMS compliance, and pharmacist 
interventions in collaboration with PAH clinicians.
• Drug utilization and interaction review were assessed for all 
patients enrolled in new PAH clinical programs.
• High cost, complex medication regimens were dispensed and 
delivered to patients safely within an average of 3.5 days to 
ensure patient continuation of therapy. 
• All medications dispensed to patients met REMS criteria to 
ensure the benefits of the medication outweigh its risks
• The majority of pharmacists reported high satisfaction with 
the PAH/REMS education, clinical resources and workflow 
implementation. 
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• PAH disease state and therapeutic assessment: examine PAH competency on disease state, symptoms 
classification, first line therapy, drug interactions and lab parameters.
• Targeted PAH/REMS assessment: examine REMS compliance, drug interactions, non-pharmacological 
counseling points, common drug adverse effects, signs and symptoms of hepatotoxicity. 
• Post- implementation assessment: Combination of general and targeted PAH competency.
Demographic
Mean values
(range or no. %)
Age, year, mean 44 (4 – 66)
Sex, female, No. (%) 5 (42.8)
Reproductive potential 2 (28.5)
New start 1  (14.2)
Continuation of therapy 8 (85.7)
PAH Medications Prescribed (n = 9)α
Bosentan (Tracleer) 4 (44.4)
Ambrisentan (Letairis) 5 (55.6)
Tadalafil (Adcirca) 4 (44.4)
Sildenafil (Revatio) 3 (33.3)
Patient Assessment
New patient assessments 9
Patient follow-up 
assessments
4
Assessment time
15 minutes 
(7-25 minutes)
Prescription Turn-Around 
Time
3.5 days 
(0 – 9 days)*
Pharmacist 
Interventions
Number of 
Encounters
Verified provider is REMS 
certified
9
Patient REMS validations 13
Drug utilization review 13
Drug interaction review 13
Lab parameters assessed 8
Lab request sent to MD 2
Required labs discussed with 
patient
12
Pregnancy risk discussed 
with patients
5
Hepatoxicity risk discussed 
with patients
8
Medication/Non-
pharmacological education 
provided
9
Drug interactions identified 1
Side effect Management 1
Therapy discontinuation due 
to adverse effects
0
Quality of life assessed 5
30.0%
40.0%
33.3% 33.3%
67%
50%
95%
50%
50.0%
60.0%
65.0%
50.0%
Management of PAH
patients
Clinical EHR review Contraceptive
Assessment
PAH DI questions
Before
After
Table 1: Patient Demographic Table 2: Pharmacist Interventions
Level of readiness is ranked based on a scale of 0 to 3:
0 = Not at all comfortable; 1 = Slightly comfortable; 2= Very comfortable; 3 = Extremely comfortable 
* 0 = same day delivery
α some patients  prescribed combination therapy
